Triacelluvax

RSS

diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Triacelluvax has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 03/07/2002

Authorisation details

Product details
Name
Triacelluvax
Agency product number
EMEA/H/C/000181
Active substance
  • Diphtheria toxoid
  • haemagglutinin filamentous
  • pertussis pertactin
  • pertussis toxin
  • tetanus toxoid
International non-proprietary name (INN) or common name
diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)
Therapeutic area (MeSH)
  • Immunization
  • Tetanus
  • Whooping Cough
  • Diphtheria
Anatomical therapeutic chemical (ATC) code
J07AJ
Publication details
Marketing-authorisation holder
Chiron S.p.A.
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
11/01/1999
Contact address
CHIRON S.p.A.,
Via Fiorentina 1,
53100, Siena
Italy

Product information

28/01/2002 Triacelluvax - EMEA/H/C/000181 -

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

TRIACELLUVAX is indicated for active immunisation of children from 6 weeks up to 7 years of age against diphtheria, tetanus and pertussis.

How useful was this page?

Add your rating